

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 86302130.9

(51) Int. Cl.: **G 01 N 33/531**
G 01 N 33/574

(22) Date of filing: 21.03.86

(30) Priority: 29.03.85 US 717345

(43) Date of publication of application:
08.10.86 Bulletin 86/41

(84) Designated Contracting States:
AT BE CH DE FR GB IT LI LU NL SE

(71) Applicant: **HYBRITECH INCORPORATED**
11095 Torreyana Road
San Diego California 92126(US)

(72) Inventor: **Berger, Tina Susan**
14211 Bernabe Court
San Diego California 92129(US)

(72) Inventor: **Ivor, Linda Patricia**
814 Moana Drive
San Diego California 92106(US)

(74) Representative: **Goldin, Douglas Michael et al,**
J.A. KEMP & CO. 14, South Square Gray's Inn
London WC1R 5EU(GB)

(54) **Processes for the stabilization of prostate specific antigen in natural matrices.**

(57) Processes for preparing stable natural matrices for prostate specific antigen (PSA) are disclosed. Biological carrier fluids for PSA obtained from a suitable mammal are modified to inhibit the activity of components of the biological fluids destabilizing to PSA. The stable natural matrices, prepared in accordance with the present invention, are useful in the measurement of PSA in a sample by means of an immunoassay.

EP 0 196 845 A2

0196845

PROCESSES FOR THE STABILIZATION OF
PROSTATE SPECIFIC ANTIGEN
IN NATURAL MATRICES

5 This invention relates to the detection and quantita-
tion of antigenic substances in fluids such as serum. More
particularly, it relates to processes for preparing stable
natural matrices for use in immunoassays for prostate specific
antigen.

10 Prostate specific antigen (PSA), a well characterized
tumor associated antigen, is a significant diagnostic and
prognostic marker in human prostatic carcinoma. As prostate
tumor cells release PSA into the bloodstream, PSA concentrations
in serum and other body fluids correlate with the progression
15 of primary or metastatic carcinoma. Accordingly, the quantitation
of PSA in patient specimens provides clinicians with an effective
means of monitoring a therapeutic regimen and evaluating remission
or progression of the disease state.

 Present immunoassays for the measurement of PSA
20 in patient fluid samples, such as the immunoradiometric assay
(IRMA) and the enzyme-linked immunosorbent assay (ELISA),
rely on the use of artificial or synthetic matrices, such
as bovine serum albumin, as calibrator matrices and as diluents.
As used herein, the term "calibrator matrix" refers to a matrix
25 in which predetermined concentrations of an antigenic substance
may be maintained for the calibration of unknown concentrations
of the antigenic substance in patient samples. The term "diluent,"
as used herein, refers to a matrix for dilution of patient
samples having concentrations of an antigenic substance which

exceed the range of the immunoassay, permitting measurement of the antigenic substance within the immunoassay range.

These matrices are used because unmodified natural matrices, such as serum-based matrices, are rendered unsuitable for use as a result of the instability of PSA upon introduction into such matrices. Specifically, it has been shown that a 30-70% loss of PSA activity occurs within 24 hours after introduction into unmodified human serum-based matrices. Further, this resultant loss of measurable PSA is not limited to human serum since PSA is also unstable upon introduction into bovine and equine serum-based matrices as well.

Because of the dissimilarity of components of such matrices to specimen components, the kinetic patterns and non-specific binding characteristics of artificial matrices may deviate significantly from serum or other body fluids containing, or suspected of containing PSA. As a result, use of these matrices is inherently a substantial limitation to immunoassays for PSA.

Accordingly, to maximize the accuracy and sensitivity of immunoassays for PSA, it is essential that matrices for calibration and sample dilution be as nearly like patient specimens, particularly with respect to non-specific binding characteristics, as possible.

Accordingly, there exists a need for means by which PSA may be stabilized in natural matrices, such as serum-based matrices, for use in the quantitative determination of PSA in patient specimens.

The present invention provides processes for the stabilization of prostate specific antigen (PSA) in natural matrices. In that regard, we have unexpectedly found that

natural matrices having kinetic patterns and non-specific binding characteristics similar to those of patient specimens can be modified so that PSA is stable therein without substantially altering their desirable properties as matrices.

5

According to the present invention, therefore, biologic fluid obtained from a suitable mammal and having kinetic patterns and non-specific binding characteristics the same or substantially the same as the patient sample is modified to inhibit the activity of components of the fluid destabilizing to PSA. In a preferred process of the invention, such biological fluid is modified by an alkaline pH shift from normal (about pH 7) to at least about pH 9 for a period of time effective to inhibit the activity of fluid components destabilizing to PSA. Thereafter, the pH of the biological fluid is decreased to about pH 7.

This invention has been summarized in order that the detailed description that follows may be better understood, and in order that the contribution to the art may be better appreciated.

As indicated above, the present invention provides a means by which natural matrices may be modified to stabilize prostate specific antigen (PSA). In the context of the present invention, the term "natural matrix" refers to a biologically occurring composition produced by living processes having kinetic patterns and non-specific binding characteristics the same as, or similar enough to, a patient sample to permit its use as a matrix. The present invention is useful for the detection and/or quantitative measurement of PSA in patient fluid samples by means of conventional immunoassay procedures.

More specifically, stable natural matrices prepared in accordance with the processes of the present invention are useful as calibrator matrices and diluents in immunoassays for PSA.

Immunoassays for the determination of concentrations of antigenic substances in fluid samples are well known to the art and need not be described in detail. However, among the immunoassays for which the present invention is particularly useful may be mentioned monoclonal antibody-based immunometric assays, such as the "two-site" or "sandwich" immunometric assays described in U.S. Patent No. 4,376,110. Additionally, among the means by which such immunoassays may be accomplished may be mentioned radiometric means, enzymatic means and fluorometric means.

In accordance with the present invention, a biological fluid obtained from a suitable mammal is utilized. For example, whole blood, serum, plasma, cerebral spinal fluid or urine may be suitably utilized in the present invention. Preferred for use is serum derived from human blood in which the presence of circulating PSA, if any, is not detectable in significant concentrations. Particularly preferred for use is serum derived from human female blood due to the absence of circulating PSA.

According to the presently preferred process of the present invention, human female serum is modified to inhibit the activity of serum components which destabilize PSA. While Applicant does not intend to be bound by any theory for the instability of PSA in unmodified serum, it is believed that such instability is attributable at least in part to the presence of circulating prostate antigen binding protein (PABG). PABG, while present in significantly elevated levels in the serum of males diagnosed as having prostatic carcinoma, has also been shown to be present in normal male and female serum.

Chu et al., Annals NYAS, Vol. 417, pp. 383-389, 1983.

Modification of human female serum to provide a stable serum-based matrix for PSA is accomplished by an alkaline pH shift to a pH of at least about pH 9 for a period of time effective to inhibit the activity of serum components destabilizing to PSA. Preferably, the serum pH is shifted to about pH 12, the serum is incubated for about 5 to about 45 minutes and thereafter the serum pH is decreased to about pH 7. Modification of the serum to effect pH changes in accordance with the present invention may be accomplished by conventional procedures well known to the art.

Additionally, it should be noted that while pH modification is the preferred means for inhibiting the activity of serum components reactive with PSA, chaotropic agents may also be utilized in the present invention. Among the chaotropic agents (i.e., agents which induce disorder to the tertiary structure of a protein) suitable for use in the present invention may be mentioned urea, KBr, KI, KSCN, guanidine and $MgCl_2$. Heat may also be used, i.e., the fluid may be heated and held at an elevated temperature for a sufficient time to inhibit the activity of the serum components. However, we have found that the pH adjustments referred to are most effective for this purpose.

The advantages of stable natural matrices prepared in accordance with the present invention when compared with synthetic matrices are apparent by reference to Table I. As the non-specific binding characteristics of such stable natural matrices are comparable to patient specimens, the sensitivity and accuracy of an immunoassay for PSA is enhanced.

Additionally, the stability of PSA in natural matrices modified in accordance with the present invention renders such matrices highly effective and desirable as calibrator

0196845

matrices and specimen diluents in immunoassays for PSA. As indicated by Tables II and III, PSA is substantially more stable in such matrices as compared with unmodified natural matrices.

5 Furthermore, it will be appreciated by those skilled in the art having the benefit of this disclosure that the present invention suggests processes for the stabilization of other antigens which are unstable upon introduction into unmodified natural matrices. For example, we have obtained
10 similar results with the tumor-associated antigen calcitonin.

The present invention may be better understood by reference to the following non-limiting example.

EXAMPLE 1

15 Preparation of pH Modified Serum

Human female serum, obtained from the Interstate Blood Bank, Memphis, Tennessee and maintained at -20°C , was used to prepare a pH modified natural matrix. 1000 ml of the serum was adjusted to approximately pH 12 by addition
20 of 17-20 ml of 10N NaOH in a vessel fitted with a stirring device. The basic serum solution was thereafter incubated for 30 minutes at $22-28^{\circ}\text{C}$ with stirring, followed by a return to approximately pH 7.0 by the addition of 15-17 ml of 10N HCl. The pH 7 solution was thereafter centrifuged for 10 minutes.
25 at 1,000 x g and filtered through a final sieve of 0.2 μ .

Alternate Method for Preparation of pH Modified Serum

Approximately 0.30 ml to 0.50 ml of 10N NaOH was added with stirring to 20 ml of pooled human female serum to increase the pH to 12.0. The basic serum was incubated
30 for 30 minutes followed by addition of 0.1M Sodium Phosphate (0.276 gm monobasic sodium phosphate) with stirring to yield a slight decrease in pH. Thereafter 0.40 ml to 0.60 ml of 6N HCl was added to adjust the pH to pH 6 and the solution

0196845

was stirred at room temperature for 2-3 hours. The pH was finally adjusted to pH 7 using approximately 0.10 ml to 0.5 ml IN NaOH.

Comparison of Non-Specific Binding

5 Non-specific binding values attributable to synthetic matrix samples comprising 5% Bovine Serum Albumin (Miles Laboratories, Inc., Elkhart, Indiana)/2% IgG (Pel-Freeze Biologicals, Rogers, Arkansas) were compared with unmodified human female serum samples and pH modified serum samples prepared as described
10 above non-specific binding values were determined using a commercially available two-site immunoradiometric assay, TANDEM®-R PSA (Hybritech Incorporated, San Diego, California). Each matrix was evaluated in a 12 replicate assay using 0.05 ml per tube in accordance with the TANDEM®-R PSA protocol with
15 an extended incubation period of 4 hours.

Table I hereinafter sets forth the average value obtained for the synthetic matrix samples, unmodified serum samples and the pH modified serum samples, respectively. The data is expressed as counts/minute and concentration of
20 PSA (ng/ml) relative to a standard curve.

Table I

	<u>Sample Matrix</u>	<u>CPM</u>	<u>PSA (ng/ml)</u>
	5% BSA/2% IgG	1179	0.24
25	Unmodified Serum	930	0.07
	pH Modified Serum	946	0.09

From Table I it is shown that the non-specific binding values obtained for the unmodified and pH modified serum samples
30 were comparable, while the non-specific binding values obtained for the synthetic samples were significantly higher.

Determination of the Stability of PSA

An accelerated stability study of PSA was performed

0196845

using unmodified human female serum and pH modified serum prepared as described above. A 10 µl quantity of 855 ng/ml PSA from seminal plasma was diluted into 990 µl of each matrix sample and maintained at 35°C. The stability of PSA, set forth in Table II as percent loss of measurable PSA, was determined for each sample at 1, 3 and 5 days relative to a -70°C control sample. By procedures well known to the art, the values obtained may be extrapolated to 1.2, 3.6 and 6.0 months, respectively at 4°C.

10

Table II

<u>Sample Matrix</u>	<u>% Loss in Measurable PSA Days at 35°C</u>		
	<u>1</u>	<u>3</u>	<u>5</u>
Unmodified	21	32	36
pH 12 modified	4	3	0
Unmodified	20	26	30
pH 12 modified	8	7	5

15

20

From Table II it is readily apparent that PSA was substantially more stable in the pH modified serum as compared with the unmodified serum.

Determination of the Recovery of PSA

25

The loss of measurable PSA from either seminal plasma or human male serum following dilution into untreated serum or serum modified as described above was determined. Into 4 tubes containing 0.4 ml of sample matrix, 0.1 ml of 125 ng/ml PSA from seminal plasma was added to yield an expected concentration of 25 ng/ml PSA. An aliquot of each solution was then diluted 1:1 into human male serum previously analyzed to contain 19.1 ng/ml PSA. Each of the four tubes were evaluated for PSA content using a commercially available two-site immuno-

30

radiometric assay, TANDEM®-R PSA, (Hybritech Incorporated, San Diego, California), with an extended incubation period of 4 hours. The resulting concentrations and calculated percent loss of PSA are shown in Table III. The data clearly indicates a highly desirable recovery of PSA for the pH modified matrix, while significant loss of PSA occurs in unmodified serum.

Table III

Addition of PSA From Seminal Plasma

	<u>PSA Expected ng/ml</u>	<u>PSA Observed ng/ml</u>	<u>PSA % Loss</u>
Unmodified Serum	25.0	12.33	51
pH Modified Serum	25.0	24.16	3

Dilutions of Solutions 1:1 with Human Serum Containing PSA

	<u>PSA Expected ng/ml</u>	<u>PSA Observed ng/ml</u>	<u>PSA % Loss</u>
Unmodified Serum	15.72	15.29	3
pH Modified Serum	21.63	22.17	0

The foregoing description has been directed to preferred embodiments of the invention in accordance with the requirements of the Patent Statutes for purposes of illustration and explanation. It will be apparent, however, to those skilled in the art that modifications and changes will be possible without departing from the spirit and scope of the invention. It is intended that the following claims be interpreted to embrace all such modifications and changes.

CLAIMS

1. A process for preparing a stable natural matrix for use in the measurement of prostate specific antigen (PSA) in a fluid sample by means of an immunoassay comprising modifying a biological carrier fluid for PSA obtained from a suitable mammal to inhibit the activity of components of said biologic fluid destabilizing to said PSA.
2. The process according to claim 1 wherein said biologic fluid comprises blood, serum or plasma.
3. The process according to claims 1 or claim 2 wherein said mammal is a human.
4. The process according to claim 3 wherein said mammal is a female.
5. The process according to claim 1 or claim 2 wherein said natural matrix is used as a calibrator matrix.
6. The process according to claim 1 or claim 2 wherein said natural matrix is used as a diluent.
7. The process according to claim 1 or claim 2 wherein said immunoassay is a monoclonal antibody-based immunometric assay.
8. The process according to claim 7 wherein said immunoassay is a "two-site" immunometric assay.

9. The process according to claim 7 wherein the said immunometric assay is accomplished by means selected from the group consisting of radiometric means, enzymatic means and fluorometric means.

5 10. The process according to claim 1 or claim 2 wherein said modifying step comprises adjusting the pH of said biological fluid to a pH, and for a period of time, effective to inhibit the destabilizing activity of components of said biological fluid.

10 11. The process according to claim 10 wherein said modifying step further comprises increasing the pH of said biological fluid to at least about pH 9 for a period of time effective to inhibit the activity of the components of said biological fluid and thereafter
15 decreasing the pH of said biological fluid to about pH 7.

 12. The process according to claim 11 wherein the pH of said biological fluid is increased to about pH 12.

 13. The process according to claim 1 or claim 2
20 wherein said modifying step comprises treating said biological fluid with a chaotropic agent for a time sufficient to inhibit the destabilizing activity of the components of the biological fluid.

14. A process for stabilizing prostate specific antigen (PSA) in a serum-based matrix for use in the measurement of said PSA in a fluid sample by means of an immunoassay comprising modifying serum obtained from a
5 suitable human female to inhibit the activity of serum components destabilizing to said PSA.

15. The process according to claim 14 wherein said serum-based matrix is used as a calibrator matrix.

16. The process according to claim 14 wherein
10 said serum-based matrix composition is used as a diluent.

17. The process according to claim 14 wherein said modifying step further comprises shifting the pH of said serum for a period of time effective to inhibit the activity of said serum components.

15 18. The process according to claim 17 wherein said modifying step further comprises increasing the pH of said serum to at least about pH 9 for a period of time effective to inhibit the activity of said serum components and thereafter decreasing the pH of said serum to about pH
20 7.

19. The process according to claim 18 wherein the pH of said serum is increased to about pH 12.

20. The process according to claim 14 wherein said modifying step comprises treating the serum with a
25 chaotropic agent for a time sufficient to inhibit the destabilizing activity of the components of the serum.

0196845

-13-

21. A stable natural matrix produced according to the process of claim 1 or claim 2 or produced according to the process of claim 11 or claim 12 or a stable serum-based matrix produced according to the
5 process of claim 17 or claim 18.

22. A process for preparing a stable natural matrix for use in the measurement of antigen in a fluid sample by means of an immunoassay comprising modifying a biological carrier fluid for antigen obtained from a
10 suitable mammal to inhibit the activity of components of said biologic fluid destabilizing to said antigen.

23. The process according to claim 22 wherein said antigen is calcitonin.